Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal

NCT05712707 is registered in ClinicalTrials.gov with New York State Psychiatric Institute as lead sponsor.

NCT NCT05712707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05712707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B Study of Sublingual Dexmedetomidine, an Alpha 2 Adrenergic Agonist, for Treating Opioid Withdrawal
Lead sponsor
New York State Psychiatric Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 28, 2023
Completion date
August 31, 2026
Enrollment
160 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

opioid use disorder, opioid withdrawal